ACLY and breast cancer: Interestingly, despite patients with high and low ACLY expression in the basal group having similar overall survival reaching more than 200 months of follow-up, high ACLY expression reduced 50% of patients’ survival probability (logRank p = 0.03), this could suggest that it served as a poor prognostic marker in patients with basal subtype of BC (Fig. 3).